sunny.png
Friday November 27th, 2020 9:34AM

WHO study finds remdesivir didn't help COVID-19 patients

By The Associated Press

GENEVA (AP) — A large study led by the World Health Organization suggests that the antiviral drug remdesivir did not help hospitalized COVID-19 patients, in contrast to an earlier study that made the medicine a standard of care in the United States and many other countries.

The results announced Friday do not negate the previous ones, and the WHO study was not as rigorous as the earlier one led by the U.S. National Institutes of Health. But they add to concerns about how much value the pricey drug gives because none of the studies have found it can improve survival.

The drug has not been approved for COVID-19 in the U.S., but it was authorized for emergency use after the previous study found it shortened recovery time by five days on average. It’s approved for use against COVID-19 in the United Kingdom and Europe, and is among the treatments U.S. President Donald Trump received when he was infected earlier this month.

The WHO study involved more than 11,000 patients in 30 countries. About 2,750 were randomly assigned to get remdesivir. The rest got either the malaria drug hydroxychloroquine, the immune-system booster interferon, the antiviral combo lopinavir-ritonavir, or just usual care. The other drugs have largely been ruled out for COVID-19 by previous studies, but not remdesivir.

Death rates after 28 days, the need for breathing machines and time in the hospital were relatively similar for those given remdesivir versus usual care.

The results have not been published in a journal or reviewed by independent scientists, but were posted on a site researchers use to share results quickly.

“The big story is the finding that remdesivir produces no meaningful impact on survival,” Martin Landray, an Oxford University professor who led other coronavirus treatment research, said in a statement.

“This is a drug that has to be given by intravenous infusion for five to 10 days,” and costs about $2,550 per treatment course, he said. “COVID affects millions of people and their families around the world. We need scalable, affordable and equitable treatments.”

Dr. Margaret Harris, a WHO spokeswoman, attributed the difference in the conclusions of the two studies to the fact WHO's was larger.

“It’s just a much higher-powered study,” she said. “It’s quadruple the number of people in all the other studies."

However, Dr. Andre Kalil, a University of Nebraska infectious disease specialist who helped lead the U.S. remdesivir study, said the WHO one was poorly designed, which makes its conclusions less reliable. Patients and doctors knew what treatment they were using, there was no placebo infusion to help avoid biased reporting of risks or benefits, there was little information about the severity of patients' symptoms when treatments began and a lot of missing data, he said.

“Poor quality study design cannot be fixed by a large sample size, no matter how large it is,” Kalil wrote in an email.

Furthermore, the WHO study tested 10 days of remdesivir, so some patients may have been hospitalized longer than they needed to be just to finish treatment, making their length of stay look bad in comparison to others getting usual care.

Remdesivir’s maker, Gilead Sciences, said in a statement that the results are inconsistent with more rigorous studies and have not been fully reviewed or published.

___

Marchione reported from Milwaukee.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

___

This story has been corrected to remove an erroneous reference to remdesivir being a repurposed malaria drug.

  • Associated Categories: Associated Press (AP), AP National News, AP Online National News, Top General short headlines, AP Health, AP World News
© Copyright 2020 AccessWDUN.com
All rights reserved. This material may not be published, broadcast, rewritten, or redistributed without permission.
WHO study finds remdesivir didn't help COVID-19 patients
A large study led by the World Health Organization suggests that the antiviral drug remdesivir did not help hospitalized COVID-19 patients
11:14AM ( 8 minutes ago )
Twitter changes hacked content rules after Biden story furor
Twitter CEO Jack Dorsey says the company was wrong to block weblinks to an unverified political story, a move that had prompted cries of censorship from the right
11:14AM ( 8 minutes ago )
Some businesses opening, expanding despite pandemic hurdles
The odds of success with a new business are always precarious
11:04AM ( 18 minutes ago )
Associated Press (AP)
Pfizer: Mid-November earliest it can seek virus vaccine OK
Pfizer CEO says it can't seek emergency authorization of its COVID-19 vaccine before the third week of November — and that's if everything goes well
10:09AM ( 1 hour ago )
Putin proposes yearlong extension of nuclear pact with US
Russian President Vladimir Putin has made a strong call to save his country's last existing nuclear arms control pact with the United States, proposing to extend it at least for one year
9:41AM ( 1 hour ago )
Virus at 'turning point' in Europe, hitting at-risk groups
Doctors are warning that Europe is at a turning point as the coronavirus surges back across the continent, including among vulnerable people, and governments try to impose restrictions without locking whole economies down
9:38AM ( 1 hour ago )
AP National News
Trump, Biden go at it — from a distance — in town halls
President Donald Trump and Democrat Joe Biden showed striking differences in temperament, views on racial justice and approaches to the pandemic that has reshaped the nation in dueling televised town halls
5:17AM ( 6 hours ago )
The Latest: Germany sees 7,000 new infections for first time
Germany has confirmed more than 7,000 new coronavirus infections for the first time, its second consecutive daily record
3:59AM ( 7 hours ago )
Virologist: Milan surge spreading to at-risk populations
As Italian health officials declare that the resurgence of COVID-19 has reached an “acute phase,” a virologist on the front lines in the Lombard capital, Milan, tells The Associated Press that Italy has two weeks to stop the spread or risk “following in the footsteps” of European neighbors where exponential spreads have ushered back harsh restrictions
3:28AM ( 7 hours ago )
AP Online National News
Ex-Mexico army chief arrested in LA on drugs, money charges
Former Mexican defense secretary Gen. Salvador Cienfuegos has been arrested in Los Angeles
12:25AM ( 10 hours ago )
Court hearing resumes in plot to kidnap Michigan governor
Five of the men accused in a plot to kidnap Michigan Gov. Gretchen Whitmer return to federal court as a hearing on whether there is enough evidence to charge them continues
11:48PM ( 11 hours ago )
Correa hits walkoff homer to keep Astros alive in ALCS
Carlos Correa homered with one out in the ninth inning and the Houston Astros beat the Tampa Bay Rays 4-3 behind sensational pitching from five rookies to remain alive in the AL Championship Series
11:03PM ( 12 hours ago )
Top General short headlines
Twitter changes hacked content rules after Biden story furor
Twitter CEO Jack Dorsey says the company was wrong to block weblinks to an unverified political story, a move that had prompted cries of censorship from the right
11:14AM ( 8 minutes ago )
Some businesses opening, expanding despite pandemic hurdles
The odds of success with a new business are always precarious
11:04AM ( 18 minutes ago )
Virus hits beach resort, as pandemic surges in Argentina
Hundreds of Argentine flags dotted the sand of a beach at the Mar del Plata resort, a poignant memorial to the victims of the novel coronavirus in one of this South American country’s virus hotspots
10:52AM ( 30 minutes ago )
Thai PM refuses to resign, police crack down on protesters
Riot police in Thailand have cracked down on thousands of student-led protesters who rallied Friday in the capital in defiance of a strict state of emergency, while the prime minister rejected calls for his resignation
10:47AM ( 35 minutes ago )
Biden out-raises Trump $383M to $248M in September
President Donald Trump was out-raised by Democrat Joe Biden in September and is being outgunned financially by his rival with just weeks to go until Election Day
10:47AM ( 35 minutes ago )